about
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinomaBiomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and chinaCinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells.Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues.Apoptosis-inducing activity of compounds screened and characterized from cinobufacini by bioassay-guided isolation.Photodynamic therapy for human hepatoma-cell-line tumors utilizing biliary excretion properties of indocyanine green.KL-6 mucin expression in carcinoma of the ampulla of Vater: association with cancer progression.Dividing phase-dependent cytotoxicity profiling of human embryonic lung fibroblast identifies candidate anticancer reagents.High Levels of Gamma-Glutamyl Transferase and Indocyanine Green Retention Rate at 15 min as Preoperative Predictors of Tumor Recurrence in Patients With Hepatocellular Carcinoma.Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers.Des-gamma-carboxyprothrombin: clinical effectiveness and biochemical importance.Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin.Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor.Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer.Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma.The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011.Research progress on natural products from traditional Chinese medicine in treatment of Alzheimer's disease.Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Preliminary investigation of five novel long non-coding RNAs in hepatocellular carcinoma cell lines.Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus.Expression of KL-6/MUC1 in pancreatic cancer tissues and its potential involvement in tumor metastasis.Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways.Intractable and rare diseases research in Asia.Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15 cells.Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis.Induction of apoptosis in human hepatocellular carcinoma cells by synthetic antineoplaston A10.Subcellular localization of KL-6 mucin in colorectal carcinoma cell lines: association with metastatic potential and cell morphology.Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.Caffeoyl pyrrolidine derivative LY52 inhibits hepatocellular carcinoma invasion via suppressing matrix metalloproteinase-2The supercritical CO₂ extract from the skin of Bufo bufo gargarizans Cantor blocks hepatitis B virus antigen secretion in HepG2.2.15 cells.New 'multi-omics' approach and its contribution to hepatocellular carcinoma in China.Intermittent clamping is superior to ischemic preconditioning and its effect is more marked with shorter clamping cycles in the rat liver.Appearance of high-molecular weight sialoglycoproteins recognized by Maackia amurensis leukoagglutinin in gastric cancer tissues: a case report using 2-DE-lectin binding analysis.Induction of apoptosis by cinobufacini preparation through mitochondria- and Fas-mediated caspase-dependent pathways in human hepatocellular carcinoma cells.Combination of Cinobufacini and Doxorubicin Increases Apoptosis of Hepatocellular Carcinoma Cells through the Fas- and Mitochondria-Mediated Pathways.Can gamma-glutamyl transferase levels contribute to a better prognosis for patients with hepatocellular carcinoma?Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma.Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma.
P50
Q26772324-A5EF20CE-2579-409E-BD0D-3F542D1E78A3Q27003291-F06647F4-88F4-469C-895B-B7D51F94A17EQ33535586-D49F3FD8-E508-4370-A7D6-91C78BBB79E3Q33829875-E3F21D3B-7E2A-4F3F-BEBC-431B802F3623Q33864675-125592B5-FD86-4B9A-85E8-14E8557957ACQ34675821-77872275-4163-4958-9E7C-8892A3EB5AB6Q35059595-B9F9CDD2-222D-4462-9FF4-6E388D1D5C53Q36122909-09C425A0-02EC-472B-B03D-16BB563CB241Q36193868-8F5BEA8D-AF29-4139-AB48-5F4438C2F8B2Q37681975-AEF53122-EE48-4F99-94B5-B72B5E305A1CQ37681994-1059D6AB-4309-4728-8644-D0870C2098A3Q37793324-9C6A6D44-4CE4-44D6-9310-38E80523A0D1Q37824078-09E0ACEC-3195-45D9-9265-324D4531FF5DQ37830241-98AA4AAB-1A0D-43D2-88C0-F417F58D86B6Q37964341-CF876BE8-8F6C-4DAE-BF9E-1748C743931EQ37995237-24389252-060F-4264-9C02-84EE9BC897AFQ38110157-56170A8A-14F8-43D8-97CB-E3EAD42EA74BQ38216010-C351C027-D41B-4AE1-BFD9-2FB68FECF3F5Q38635603-1949C50F-F9A5-419B-82F1-7D2886040EE5Q38753237-81DF3AD4-133D-4BB3-984C-C0856867EF2DQ38878957-854C2DF5-9C11-4A20-BB22-F03829526B67Q39535399-FC5518CE-B529-4AC0-89CA-A2FA0112EC3BQ39542386-5955A177-F737-4AD7-A13D-47E704A00308Q39599072-B0A2A01A-9FD7-46DB-BA1F-5CAD18BFA512Q39614087-EDF8F7A2-9298-4DBE-9BED-39EF02D87469Q39647062-98238261-7C33-4FCB-935B-F2C609D74018Q39706817-B6C25796-40AB-4A95-889B-A9D846A4281CQ40094849-F7EDC8CA-0FEA-4249-A4B8-C6DDF60C8DC8Q40153525-02F9355A-3551-4A32-8FF1-F3333CF2DFB5Q41670194-DDBBD19A-F743-4426-BF78-618F74F2B995Q42089632-96112B75-C29D-43B6-80BD-BBF5078BCCF4Q42230367-9AFEA599-3AFA-4574-9527-6780B70C34FAQ43084659-E078AF1C-AED6-42AC-ADDF-A781987F0841Q45359408-18BBB28D-0435-46D7-9294-4A898723B011Q47223125-13F1FB82-C14B-43E4-8389-DF314315C0E5Q47256364-D921FC31-65CA-4951-AB34-1647458ED9E4Q47745678-B576C222-2DE1-4E41-82B7-0F05ECD0830FQ50452969-55726041-757B-42A9-A674-50E008FB9FFFQ51787201-66669B6E-84F7-4A85-A15A-170D0A2CA665Q52715532-5C65206E-49E9-4F20-8389-384264745B97
P50
name
Yoshinori Inagaki
@en
type
label
Yoshinori Inagaki
@en
prefLabel
Yoshinori Inagaki
@en